Log In
BCIQ
Print this Print this
 

BI 1361849, CV9202

  Manage Alerts
Collapse Summary General Information
Company CureVac AG
Description mRNA-based vaccine that codes for 6 antigens: melanoma-associated antigen family C1 (MAGEC1), MAGEC2, cancer/testis antigen 1B (CTAG1B; NY-ESO-1), survivin (BIRC5), oncofetal antigen 5T4 and mucin 1 (MUC1; CD227).
Molecular Target Melanoma-associated antigen C1 (MAGEC1) ; Melanoma-associated antigen C2 (MAGEC2)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerBoehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$601.7M

$45.3M

$556.4M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/18/2014

$601.7M

$45.3M

$556.4M

Get a free BioCentury trial today